immunAware

HLA-A*02:01 | easYmer kit

Product Code:
 
IMM-1002-01
Product Group:
 
MHC Tetramers
Supplier:
 
immunAware
Regulatory Status:
 
RUO
Shipping:
 
Dry Ice
Storage:
 
-20 °C
 

No additional charges, what you see is what you pay! *

CodeSizePrice
IMM-1002-01-05050 Tests£956.00
Quantity:
IMM-1002-01-100100 Tests£1,220.00
Quantity:
IMM-1002-01-150150 Tests£1,749.00
Quantity:
IMM-1002-01-200200 Tests£2,278.00
Quantity:
IMM-1002-01-250250 Tests£2,807.00
Quantity:
IMM-1002-01-300300 Tests£3,336.00
Quantity:
IMM-1002-01-500500 Tests£3,865.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Denmark.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Description:
HLA-Class I easYmer® is a highly active formulation of peptide-receptive HLA class I (HLA-I) molecules (no artificial Cys-bonds linking heavy chain and b2m). Add Peptides of interest to generate specific peptide-HLA class I monomers. The loading efficacy can be validated in a FACS-based bead assay. The monomers can easily be tetramerised with fluorophore-conjugated streptavidin and used to stain cognate T cells for analysis in a flow cytometric assay. The easYmer® technology seamlessly enables: Large-scale production of pMHC monomers with a single epitope for screening a large number of samples, parallel production and screening of pMHC monomers with many different peptide epitope candidates and screening and validation of peptide-HLA-I binding. easYmers® are available in aliquots of 50 Tests (corresponding to 20 ug of pMHC)

References

  • Luxenburger, H. et. al.; Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients; Journal of hepatology; 2023; 78(5):1017-1027PubMed ID:36804404; DOI: 10.1016/j.jhep.2023.02.007; https://www.sciencedirect.com/science/article/pii/S0168827823000958
  • Azoury, ME; et. al.; CD8+ T Cells Variably Recognize Native Versus Citrullinated GRP78 Epitopes in Type 1 Diabetes; Diabetes; 2021; 70(12):2879-2891PubMed ID:34561224; DOI: 10.2337/db21-0259; https://diabetesjournals.org/diabetes/article-abstract/70/12/2879/139067
  • Minervina, AA; et.al.; SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells; Nature immunology; 2022; 23(5):781-790PubMed ID:35383307; DOI: 10.1038/s41590-022-01184-4; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106845
  • Reinscheid, M; et.al.; COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation; Nature communications; 2022; 13(1):4631PubMed ID:35941157; DOI: 10.1038/s41467-022-32324-x; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358914
  • Oberhardt, V; et.al.; Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine; Nature; 2021; 597(7875):268-273PubMed ID:34320609; DOI: 10.1038/s41586-021-03841-4; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426185
  • Bont?, PE; et.al.; Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides; Cell reports; 2022; 39(10):110916PubMed ID:35675780; DOI: 10.1016/j.celrep.2022.110916; https://www.sciencedirect.com/science/article/pii/S2211124722006933
  • Acevedo, GR; et.al.; In Silico Guided Discovery of Novel Class I and II Trypanosoma cruzi Epitopes Recognized by T Cells from Chagas' Disease Patients; Journal of immunology (Baltimore, Md. : 1950); 2020; 204(6):1571-1581PubMed ID:32060134; DOI: 10.4049/jimmunol.1900873; https://journals.aai.org/jimmunol/article/204/6/1571/107771
  • Lee, Y; Liou, C; Liu, I; Chang, J;; T cell immunity of the nonadjuvanted HLA-restricted peptide COVID-19 vaccine; Research Square; 2023; ():PubMed ID:; DOI: 10.21203/rs.3.rs-2119898/v1; https://www.researchsquare.com/article/rs-2119898/latest
  • Bigot, J; et.al.; Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes; Cancer discovery; 2021; 11(8):1938-1951PubMed ID:33811047; DOI: 10.1158/2159-8290.CD-20-0555; https://aacrjournals.org/cancerdiscovery/article-abstract/11/8/1938/666209
  • Gonzalez-Duque, S; et.al.; Conventional and Neo-antigenic Peptides Presented by ? Cells Are Targeted by Circulating Na?ve CD8+ T Cells in Type 1 Diabetic and Healthy Donors; Cell metabolism; 2018; 28(6):946-960.e6PubMed ID:30078552; DOI: 10.1016/j.cmet.2018.07.007; https://www.sciencedirect.com/science/article/pii/S1550413118304509
  • Merlotti, A; et.al.; Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer; Science immunology; 2023; 8(80):eabm6359PubMed ID:36735774; DOI: 10.1126/sciimmunol.abm6359; https://www.science.org/doi/abs/10.1126/sciimmunol.abm6359
  • Schulien, I; et.al.; Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells; Nature medicine; 2021; 27(1):78-85PubMed ID:33184509; DOI: 10.1038/s41591-020-01143-2; https://www.nature.com/articles/s41591-020-01143-2
  • Vecchio, F; et.al.; Coxsackievirus infection induces direct pancreatic ?-cell killing but poor anti-viral CD8+ T-cell responses; bioRxiv : the preprint server for biology; 2023; ():PubMed ID:37662376; DOI: 10.1101/2023.08.19.553954; https://www.ncbi.nlm.nih.gov/pubmed/37662376
  • Zimmermann, C; et.al.; Diverse cytomegalovirus US11 antagonism and MHC-A evasion strategies reveal a tit-for-tat coevolutionary arms race in hominids; Proceedings of the National Academy of Sciences of the United States of America; 2024; 121(9):e2315985121PubMed ID:38377192; DOI: 10.1073/pnas.2315985121; https://www.pnas.org/doi/abs/10.1073/pnas.2315985121
  • Pavlidis, MA;Viborg, N;Lausen, M;R?n?, B;Kleine-Kohlbrecher, D;; Refined analytical pipeline for the pharmacodynamic assessment of T-cell responses to vaccine antigens; Frontiers in immunology; 2024; 15():1404121PubMed ID:38720900; DOI: 10.3389/fimmu.2024.1404121; https://www.frontiersin.org/articles/10.3389/fimmu.2024.1404121/full
  • Lee, Y;Liou, C;Liu, I;Chang, J;; T-cell immunity induced by a nonadjuvanted HLA-restricted peptide COVID-19 vaccine; Research Square; 2024; ():PubMed ID:; DOI: 10.21203/rs.3.rs-4411027/v1; https://www.researchsquare.com/article/rs-4411027/latest
  • Cieri, N; et.al.; Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation; Nature biotechnology; 2024; ():PubMed ID:39169264; DOI: 10.1038/s41587-024-02348-3; https://www.nature.com/articles/s41587-024-02348-3
  • Lee, YR; Liou, CW; Liu, IH; Chang, JM;; A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein; Scientific reports; 2024; 14(1):20579PubMed ID:39242614; DOI: 10.1038/s41598-024-71663-1; https://www.researchsquare.com/article/rs-4411027/latest
  • Vecchio, F; et.al.; Coxsackievirus infection induces direct pancreatic ? cell killing but poor antiviral CD8+ T cell responses; Science advances; 2024; 10(10):eadl1122PubMed ID:38446892; DOI: 10.1126/sciadv.adl1122; http://dx.doi.org/10.1126/sciadv.adl1122
  • Pulliam, T; et.al.; Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses; Journal for immunotherapy of cancer; 2024; 12(10):PubMed ID:39401968; DOI: 10.1136/jitc-2024-009803; http://dx.doi.org/10.1136/jitc-2024-009803
  • Shoumariyeh, K; et.al.; Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma; Vaccines; 2024; 12(11):PubMed ID:39591152; DOI: 10.3390/vaccines12111249; http://dx.doi.org/10.3390/vaccines12111249